Neonatal and Obstetric Provider Perceptions and Management at 22 Weeks' Gestation
American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e879-e885
DOI: 10.1055/a-1969-1237 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Nitya Nair Shah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia. Hauptthemen laut MEDLINE: Gestational Age, Infant, Extremely Premature. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objective
Active treatment for periviable infants may be influenced by neonatal and obstetric provider perceptions of prognosis. The two aims of this study are to (1) quantify prognostic discordance between provider and data-driven survival estimates and (2) evaluate if prognostic discordance is associated with the threshold probability of survival at which neonatal providers recommend active treatment or obstetric providers recommend antenatal corticosteroids. Study Design Provider survival estimates and threshold probabilities of survival for active treatment and antenatal steroid use were obtained from a case-based survey for an infant or pregnancy at 22 weeks' gestation that was administered at two Atlanta hospitals. Data-driven survival estimates, including ranges, were acquired through the National Institute of Child Health and Human Development Extremely Preterm Birth Outcomes Tool. Prognostic discordance was calculated as the difference between a provider and data-driven estimates and classified as pessimistic (provider estimate below data-driven estimate range), accurate (within range), or optimistic (above range). The association between prognostic discordance and the threshold probability of survival was evaluated using nonparametric tests.
Results
We had 137 neonatal respondents (51% response rate) and 57 obstetric responses (23% response rate). The overall median prognostic discordance was 1.5% (interquartile range: 17, 13) and 52 (27%) of all respondents were pessimistic, 100 (52%) were accurate, and 42 (22%) were optimistic. The survival threshold above which neonatal and obstetric providers recommended active treatment or antenatal corticosteroids was 30% (20–45%) and 10% (0–20%), respectively. Thresholds did not significantly differ among the three prognostic discordance groups (p = 0.45 for neonatal and p = 0.53 for obstetric providers). There was also no significant correlation between the magnitude of prognostic discordance and thresholds.
Conclusion
Prognostic discordance exists among both neonatal and obstetric providers. However, this discordance is not associated with the threshold probability of survival at which providers recommend active treatment or antenatal corticosteroids at 22 weeks' gestation. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia.
- Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia.
ORCID-Profile: Ravi Mangal Patel
Zitieren
APA
Nair Shah, N., Krishna, I., Vyas-Read, S., & Patel, R. M. (2024). Neonatal and Obstetric Provider Perceptions and Management at 22 Weeks' Gestation. American Journal of Perinatology, 41(S 01 S 01), e879-e885. https://doi.org/10.1055/a-1969-1237
Vancouver
Nair Shah N, Krishna I, Vyas-Read S, Patel RM. Neonatal and Obstetric Provider Perceptions and Management at 22 Weeks' Gestation. American Journal of Perinatology. 2024;41(S 01 S 01):e879-e885. doi:10.1055/a-1969-1237
BibTeX
@article{NairShah2024,
author = {Nair Shah, Nitya and Krishna, Iris and Vyas-Read, Shilpa and Patel, Ravi Mangal},
title = {Neonatal and Obstetric Provider Perceptions and Management at 22 Weeks' Gestation},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {S 01 S 01},
pages = {e879--e885},
doi = {10.1055/a-1969-1237}
}
EUVIMED